<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3105222110
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LIPANTHYL 200MG MICRONISED CAPS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENOFIBRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        44.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Astrea Fontaine" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Astrea Fontaine
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lipanthyl 200 Micronised belongs to a group of medicines, commonly known as<br />&#39;fibrates&#39;. These medicines are used to lower the level of fats (lipids) in the blood. For<br />example the fats known as &#39;triglycerides&#39;.<br />This medication is recommended for the treatment of hypercholesterolaemia<br />(abnormally elevated levels of cholesterol in the blood) and/or hypertriglyceridaemia<br />(abnormally elevated levels of triglycerides - fats - in the blood) in adults, when the<br />response to an appropriate and correctly observed diet is inadequate<br />Lipanthyl 200 Micronised can be used in addition to other medicines (called &#39;statins&#39;) in<br />some circumstances when levels of fats in the blood are not controlled with a statin<br />alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;You are allergic to fenofibrate or any of the other ingredients of this medicine<br />(listed in Section 6: Contents of the pack and other information)</p><p>&bull; While taking other medicines, you have had an allergic reaction or skin damage<br />from sunlight or UV light (these medicines include other fibrates and an antiinflammatory<br />medicine called &#39;ketoprofen&#39;)<br />&bull; You have severe liver, kidney or gallbladder problems<br />&bull; You have pancreatitis (an inflamed pancreas which causes abdominal pain),<br />which is not caused by high levels of fat in the blood</p><p>Do not take Lipanthyl 200 Micronised if any of the above apply to you. If you are not<br />sure, talk to your doctor or pharmacist before taking Lipanthyl 200 Micronised.<br />Warnings and Precautions<br />Talk to your doctor or pharmacist or nurse before taking Lipanthyl 200 Micronised if:</p><p>&bull; You have any liver or kidney problems<br />&bull; You may have an inflamed liver (hepatitis) - signs include yellowing of the skin<br />and the whites of the eyes (jaundice) and an increase in liver enzymes (shown<br />in blood tests)<br />&bull; You have an under-active thyroid gland (hypo-thyroidism)<br />&bull; You have diabetes, especially Type 2 diabetes, that is not well controlled<br />&bull; You have problems with certain proteins in your blood<br />&bull; You are taking other medicines<br />&bull; You or your family have had muscle problems<br />&bull; You are over 70 years of age</p><p>(Some of the above conditions can lead to high levels of lipids in your blood and need to<br />be corrected before you start therapy with fenofibrate).<br />If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist<br />before taking Lipanthyl 200 Micronised.<br />Your doctor might want to test your blood or urine to check if Lipanthyl 200 Micronised<br />is working properly and also if your kidneys, muscles and liver are working properly.<br />Effects on muscles<br />Stop taking Lipanthyl 200 Micronised and see a doctor straight away if you get<br />unexplained cramps or painful, tender or weak muscles while taking this medicine.</p><p>&bull; This is because this medicine may cause muscle problems, which may be<br />serious<br />&bull; These problems are rare but include muscle inflammation and breakdown. This<br />can cause kidney damage or even death</p><p>Your doctor may do a blood test to check your muscles before and after starting<br />treatment.<br />The risk of muscle breakdown is higher in some patients. Tell your doctor if:<br />&bull; You are over 70 years old<br />&bull; You have kidney problems<br />&bull; You have thyroid problems<br />&bull; You or a close family member has a muscle problem which runs in the family</p><p>&bull; You drink large amounts of alcohol<br />&bull; You are taking medicines called statins to lower cholesterol - such as<br />simvastatin, atorvastatin, pravastatin, rosuvastatin or fluvastatin<br />&bull; You have ever had muscle problems during treatment with statins or fibrates -<br />such as fenofibrate, bezafibrate or gemfibrozil</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before taking<br />Lipanthyl 200 Micronised.<br />Other medicines and Lipanthyl 200 Micronised<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines, including medicines obtained without a prescription.<br />In particular tell your doctor or pharmacist if you are taking any of the following<br />medicines:</p><p>&bull; Anti-coagulants to thin your blood (such as warfarin)<br />&bull; Other medicines to control fat levels in the blood (such as statins or fibrates).<br />Taking a statin at the same time as Lipanthyl 200 Micronised may increase the<br />risk of muscle problems<br />&bull; A particular class of medicines to treat diabetes (such as rosiglitazone or<br />pioglitazone)<br />&bull; Cyclosporin - used to suppress your immune system</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist<br />before taking Lipanthyl 200 Micronised.<br />Lipanthyl 200 Micronised with food and drink<br />It is important to take the capsule with food - it will not work as well if your stomach is<br />empty.</p><p>Pregnancy, breast-feeding and fertility<br />&bull; Do not take Lipanthyl 200 Micronised and tell your doctor if you are pregnant,<br />think you might be pregnant or are planning to have a baby<br />&bull; Do not take Lipanthyl 200 Micronised if you are breast-feeding or planning to<br />breast-feed your baby.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />This medicine will not affect you being able to drive or use tools or machines.<br />Important information about some of the ingredients of Lipanthyl 200 Micronised<br />Lipanthyl 200 Micronised contains lactose (a type of sugar). If you have been told by<br />your doctor that you cannot tolerate or digest some sugars (have an intolerance to<br />some sugars), talk to your doctor before taking this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>3. How to take Lipanthyl 200 Micronised<br />Always take this medicine exactly as your doctor or pharmacist has told you. Also,<br />please read the label on the packet. You should check with your doctor or pharmacist if<br />you are not sure.</p><p>Your doctor will determine the appropriate strength for you, depending on your<br />condition, your current treatment and your personal risk status.<br />Taking this medicine<br />&bull; Swallow the capsule whole with a glass of water<br />&bull; Do not open or chew the capsule<br />&bull; Take the capsule with food - it will not work as well if your stomach is empty</p><p>How much to take<br />The recommended dose for adults is one capsule of Lipanthyl 200 Micronised 200 a<br />day, taken at mealtimes.<br />Use in children and adolescents<br />The use of Lipanthyl 200 Micronised is not recommended in children under the age of<br />18.<br />People with kidney problems<br />If you have kidney problems, your doctor may tell you to take a lower dose. Ask your<br />doctor or pharmacist about this.<br />If you take more Lipanthyl 200 Micronised than you should<br />If you take more Lipanthyl 200 Micronised than you should or if someone else has taken<br />your medicine, contact your nearest hospital casualty department or tell your doctor<br />immediately.<br />If you forget to&nbsp;take Lipanthyl 200 Micronised</p><p>&bull; If you forget a dose, take the next dose with your next meal<br />&bull; Then take your next capsule at the normal time<br />&bull; Do not take a double dose to make up for a forgotten dose</p><p>If you are worried about this talk to your doctor.<br />If you stop taking Lipanthyl 200 Micronised<br />Do not stop taking Lipanthyl 200 Micronised unless your doctor tells you to, or the<br />capsules make you feel unwell. This is because abnormal levels of fats in the blood<br />need treating for a long period of time.<br />Remember that as well as taking Lipanthyl 200 Micronised it is also important that you:</p><p>&bull; Have a low fat diet<br />&bull; Take regular exercise</p><p>If you have any further questions on the use of this product, ask your doctor or<br />pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />Stop taking Lipanthyl 200 Micronised and see a doctor straight away, if you<br />notice any of the following serious side effects &mdash; you may need urgent medical<br />treatment:</p><p>&bull; Allergic reaction - the signs may include swelling of the face, lips, tongue or<br />throat, which may cause difficulty in breathing<br />&bull; Cramps or painful, tender or weak muscles - these may be signs of muscle<br />inflammation or breakdown, which can cause kidney damage or even death<br />&bull; Stomach pain - this may be a sign that your pancreas is inflamed (pancreatitis)<br />&bull; Chest pain and feeling breathless - these may be signs of a blood clot in the<br />lung (pulmonary embolism)<br />&bull; Pain, redness or swelling in the legs - these may be signs of a blood clot in the<br />leg (deep vein thrombosis)<br />&bull; Yellowing of the skin and whites of the eyes (jaundice), or an increase&nbsp;in liver<br />enzymes - these may be signs of an inflamed liver (hepatitis)</p><p>Stop taking Lipanthyl 200 Micronised and see a doctor straight away, if you notice any<br />of the side effects above.<br />Other side effects include:<br />Common (affects less than 1 in 10 people):<br />&bull; Diarrhoea<br />&bull; Stomach pain<br />&bull; Wind (flatulence)<br />&bull; Feeling sick (nausea)<br />&bull; Being sick (vomiting)<br />&bull; Raised levels of liver enzymes in the blood - shown in tests<br />&bull; Increase in homocysteine (too much of this amino acid in the blood has been<br />associated to a higher risk of coronary heart disease, stroke and peripheral<br />vascular disease, although a causal link has not been established)</p><p>Uncommon (affects less than 1 in 100 people):<br />&bull; Headache<br />&bull; Gallstones<br />&bull; Reduced sex drive<br />&bull; Rash, itching or red patches on the skin<br />&bull; Increase in &#39;creatinine&#39; produced by the kidneys - shown in tests<br />&bull; Pancreatitis (inflammation of the pancreas leading to abdominal pain)<br />&bull; Thromboembolism: pulmonary embolism (blood clot in the lung causing chest<br />pain and breathlessness), deep vein thrombosis (blood clot in the leg causing<br />pain, redness or swelling)<br />&bull; Muscle pain, muscle inflammation, muscle cramps and weakness</p><p>Rare (affects less than 1 in 1,000 people):<br />&bull; Hair loss<br />&bull; Increase in &#39;urea&#39; produced by the kidneys - shown in tests<br />&bull; Increased sensitivity of your skin to sunlight, sun lamps and sunbeds</p><p>&bull; Drop in haemoglobin (that carries oxygen in the blood) and white blood cells -<br />shown in tests.<br />&bull; Hepatitis (inflammation of the liver), symptoms of which may be mild jaundice<br />(yellowing of the skin and whites of the eyes), stomach pain and itching<br />&bull; Hypersensitivity (allergic reaction)</p><p>Side effect where the chance of it happening are not known<br />&bull; Severe form of skin rash with reddening, peeling and swelling of the skin that<br />resembles severe burns<br />&bull; Long-term lung problems<br />&bull; Muscle breakdown<br />&bull; Complications of gallbladder stones<br />&bull; Jaundice<br />&bull; Feeling dizzy (vertigo)<br />&bull; Feeling exhausted (fatigue)</p><p>If you get any unusual breathing discomfort, tell your doctor straight away<br />If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any<br />side effects not listed in this leaflet.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any<br />possible side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the safety of this<br />medicine.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Keep this medicine in the original package in order to protect from moisture.<br />Store below 30&deg;C.<br />Shelf life: 3 years<br />Do not use Lipanthyl 200 Micronised after the expiry date which is stated on the carton<br />and the blister after EXP. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will help<br />to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Lipanthyl 200 Micronised contains<br />The active substance is fenofibrate. Each Lipanthyl 200 Micronised capsule contains<br />200 milligrams (mg) of fenofibrate.<br />The other ingredients are: lactose monohydrate, sodium lauryl sulfate, pregelatinised<br />starch, crospovidone and magnesium stearate.<br />The capsule is made of gelatin, titanium dioxide (E171), iron oxide (E172), erythrosin<br />(E127).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Lipanthyl 200 Micronised looks like and contents of the pack
Lipanthyl 200 Micronised is supplied to you as ochre, hard gelatin capsules.
Lipanthyl 200 Micronised is provided in blister packs of 10, 28 or 30 capsules.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Abbott Laboratories Ltd.<br />Abbott House, Vanwall Business park<br />Vanwall Road, Maidenhead Berkshire<br />SL6 4XE, UK</p><p>Manufacturer:<br />Recipharm Fontaine<br />Rue des Pr&eacute;s Potets - 21121 FONTAINE LES DIJON &ndash; France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي ليبانثيل 200 المسحوق إلى مجموعة الأدوية المعروفة باسم &quot;فيبرات&quot;. تُستخدم هذه الأدوية في تخفيض مستوى الدهون&nbsp;في الدم. على سبيل المثال، الدهون المعروفة باسم &rsquo;الدهون الثلاثية&lsquo;.</p><p>يستعمل هذا الدواء من أجل تخفيض الدهنيات في الدم )في حالة الارتفاع غير العادي لمعدل الكولسترول في الدم( و/ أو )في&nbsp;حالات الارتفاع غير العادي لمعدل الترايجلسيريد &ndash; الدهنيات &ndash; في الدم( لدى البالغين عندما تكون الحمية المتبعة غير كافية.</p><p>يمكن استخدام ليبانثيل 200 المسحوق إلى جانب أدوية أخرى )تُسمى &rsquo;الستاتينات&lsquo;( في بعض الظروف عندما لا تكون&nbsp;مستويات الدهون في الدم تحت السيطرة بالستاتين وحده.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول ليبانثيل 200 المسحوق إذا كنت:</p><p>&bull; مصابًا بالحساسية تجاه فينوفيبرات أو أي مكون آخر من مكونات هذا الدواء )والمدرجة في القسم 6: محتويات<br />العبوة ومعلومات أخرى(<br />&bull; أثناء تناول الأدوية الأخرى، تعرضت لتفاعل حساسية أو ضرر في البشرة من ضوء الشمس أو الأشعة فوق<br />البنفسجية )تشمل هذه الأدوية الفيبرات الأخرى ودواء مضاد للالتهاب يُسمى &rsquo;كيتوبروفين&lsquo;(<br />&bull; تعاني من مشكلات حادة بالكبد أو الكلى أو المرارة<br />&bull; مصابًا بالتهاب البنكرياس )بنكرياس ملتهب يؤدي إلى ألم في المعدة(، وهو ما لا ينتج عن مستويات مرتفعة من<br />الدهون في الدم.</p><p>لا تتناول ليبانثيل 200 المسحوق إذا انطبق عليك أي مما سبق. إذا لم تكن متأكدًا، فتحدث مع طبيبك أو الصيدلاني قبل تناول<br />ليبانثيل 200 المسحوق.</p><p>تحذيرات واحتياطات<br />تحدث مع طبيبك أو الصيدلاني أو الممرضة قبل تناول ليبانثيل 200 المسحوق إذا كنت:<br />&bull; تعاني من أي مشاكل بالكبد أو الكلى<br />&bull; مصابًا بالتهاب في الكبد - تشمل العلامات اصفرار البشرة وبياض العينين )اليرقان( وزيادة إنزيمات الكبد )تظهر<br />في اختبارات الدم(<br />&bull; لديك غدة درقية منخفضة النشاط )انخفاض التدرق(<br />&bull; مصابًا بالسكري، وخاصة النوع الثاني من السكري الذي لا يخضع لتحكم جيد<br />&bull; تعاني من مشاكل في بروتينات معينة في دمك<br />&bull; تتناول أدوية أخرى<br />&bull; تعرضت أو تعرض أحد أفراد أسرتك لمشاكل في العضلات<br />&bull; أكبر من 70 عامًا</p><p>(يمكن أن تؤدي بعض الحالات المذكورة أعلاه إلى مستويات مرتفعة من الدهون في دمك وتحتاج إلى تصحيح قبل أن تبدأ في<br />العلاج باستخدام فينوفيبرات).<br />إذا انطبق أيٌ مما سبق عليك (أو إذا لم تكن متأكدًا)، فتحدث مع الطبيب أو الصيدلاني قبل تناول ليبانثيل 200 المسحوق.<br />قد يحتاج طبيبك إلى إجراء اختبار للدم أو البول للتحقق مما إذا كان ليبانثيل 200 المسحوق يعمل بالشكل الملائم وكذلك إذا<br />كانت كليتاك وعضلاتك وكبدك يعملون بالشكل الملائم.</p><p>الآثار على العضلات<br />توقف عن تناول ليبانثيل 200 المسحوق، واذهب إلى الطبيب فورًا إذا تعرضت لشد عضلي بلا مبرر أو ألم أو لين أو ضعف<br />في العضلات أثناء تناول هذا الدواء.<br />&bull; وهذا لأن هذا الدواء قد يتسبب في مشاكل في العضلات وهو ما قد يكون خطيرًا<br />&bull; هذه المشاكل نادرة لكنها تشمل التهاب العضلات وانهيارها. يمكن أن يؤدي هذا إلى أضرار للكبد وإلى الوفاة كذلك</p><p>قد يُجري طبيبك اختبارًا للدم لفحص عضلاتك قبل بدء العلاج وبعده<br />يزداد خطر انهيار العضلات لدى بعض المرضى. أبلغ طبيبك إذا كنت:</p><p>&bull; أكبر من 70 عامًا<br />&bull; تعاني من مشكلات في الكلى<br />&bull; تعاني من مشاكل في الغدة الدرقية<br />&bull; تعرضت أو تعرض أحد أفراد الأسرة المقربين لمشكلة في العضلات وتنتشر بين أفراد الأسرة<br />&bull; تشرب كميات كبيرة من الكحول<br />&bull; تتناول أدوية تُسمى الستاتينات لخفض الكولسترول - مثل سيمفاستاتين أو أتورفاستاتين أو برافاستاتين أو<br />روزوفاستاتين أو فلوفاستاتين<br />&bull; عانيت من قبل من مشاكل في العضلات أثناء العلاج بالستاتينات أو الفيبرات، مثل فينوفيبرات أو بيزافيبرات أو<br />جمفبروزيل</p><p>إذا انطبق أيٌ مما سبق عليك )أو إذا لم تكن متأكدًا(، فتحدث مع طبيبك قبل تناول ليبانثيل 200 المسحوق.</p><p>الأدوية الأخرى وليبانثيل 200 المسحوق<br />يُرجى إخبار الطبيب أو الصيدلاني في حالة تناول أدوية أخرى مؤخرًا أو في الوقت الحالي، بما في ذلك الأدوية التي تصرف<br />دون وصفة طبية.<br />وبشكلٍ خاص، أخبر طبيبك أو الصيدلاني إذا كنت تتناول أي دواء من الأدوية التالية:</p><p>&bull; مثبطات التجلط لتسييل الدم )مثل وارفارين(<br />&bull; أدوية أخرى للتحكم في مستويات الدهون في الدم )مثل الستاتينات أو الفيبرات(. قد يؤدي تناول ستاتين في نفس<br />الوقت مع ليبانثيل 200 المسحوق إلى زيادة خطر مشاكل العضلات<br />&bull; فئة معينة من الأدوية لعلاج السكري )مثل روزيجليتازون أو بيوغليتازون(<br />&bull; سايكلوسبورين - يُستخدم لكبت جهازك المناعي</p><p>إذا انطبق أيٌ مما سبق عليك )أو إذا لم تكن متأكدًا(، فتحدث مع الطبيب أو الصيدلاني قبل تناول ليبانثيل 200 المسحوق.</p><p>تناول ليبانثيل 200 المسحوق مع الطعام والشراب<br />من المهم أن تتناول الكبسولة مع الطعام - لن تكون فعالة بالقدر نفسه إذا كانت معدتك فارغة.</p><p>الحمل والرضاعة الطبيعية والخصوبة<br />&bull; توقفي عن تناول ليبانثيل 200 المسحوق وأخبري طبيبكِ إذا كنتِ حاملًا أو تعتقدين أنك حامل أو تخططين للحمل<br />&bull; لا تتناولي ليبانثيل 200 المسحوق إذا كنت ترضعين رضاعة طبيعية أو تنوين إرضاع طفلك رضاعة طبيعية.<br />استشيري طبيبكِ أو الصيدلاني قبل تناول أي دواء.</p><p>القيادة واستخدام الآلات<br />لن يؤثر هذا الدواء في قدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p>معلومات مهمة عن بعض مكونات ليبانثيل 200 المسحوق<br />يحتوي ليبانثيل 200 المسحوق على لاكتوز )نوع من السكر(. إذا أخبرك طبيبك بأنك لا تستطيع تحمل بعض السكريات أو<br />هضمها، فتحدث مع طبيبك قبل تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب أو الصيدلاني. ويرجى كذلك قراءة الملصق على العبوة. يجب<br />استشارة طبيبكِ أو الصيدلاني إذا لم تكوني متأكدة.<br />سيحدد طبيبك التركيز الملائم لك على حسب حالتك وعلاجك الحالي وحالة الخطر الشخصي عليك.</p><p>تناول هذا الدواء</p><p>&bull; ابتلع الكبسولة بأكملها مع كوب من الماء<br />&bull; لا تفتح الكبسولات أو تمضغها<br />&bull; تناول الكبسولة مع الطعام - لن تكون فعالة بالقدر نفسه إذا كانت معدتك فارغة</p><p>مقدار الجرعة<br />تبلغ الجرعة الموصى بها للبالغين كبسولة واحدة من ليبانثيل 200 المسحوق في اليوم ويتم تناولها مع الأكل.<br />الاستخدام مع الأطفال والمراهقين<br />لا يوصى باستخدام ليبانثيل 200 المسحوق للأطفال الأقل من 18 عامًا.<br />من يعانون من مشاكل في الكلى<br />إذا كنت تعاني من مشاكل في الكلى، فقد يبلغك طبيبك بأن تتناول جرعة أقل. اسأل الطبيب أو الصيدلاني بشأن هذا الأمر.<br />في حالة تناولك جرعة أكبر مما ينبغي من ليبانثيل 200 المسحوق</p><p>إذا تناولت جرعة أكبر مما ينبغي من ليبانثيل 200 المسحوق أو إذا تناول شخص آخر دواءك، فتواصل مع إدارة الطوارئ<br />في أقرب مستشفى إليك أو أبلغ طبيبك على الفور.<br />في حالة نسيانك تناول ليبانثيل 200 المسحوق<br />&bull; إذا نسيت جرعة، فتناول الجرعة التالية مع وجبتك التالية<br />&bull; ثم تناول كبسولتك التالية في الموعد المعتاد.<br />&bull; لا تتناول جرعة مزدوجة لتعويض الجرعة المنسية</p><p>إذا كنت قلقًا بشأن هذا، فتحدث مع طبيبك.<br />إذا توقفت عن تناول ليبانثيل 200 المسحوق<br />لا توقف ليبانثيل 200 المسحوق إلا إذا طلب منك طبيبك، أو إذا كانت الكبسولات تجعلك تشعر بعدم الراحة. وهذا لأن<br />المستويات غير العادية من الدهون في الدم تحتاج إلى علاج لفترة طويلة.<br />تذكر أنه إلى جانب تناول ليبانثيل 200 المسحوق، من المهم لك أيضًا أن:</p><p>&bull; تأكل طعامًا منخفض الدهون<br />&bull; تمارس تمارين منتظمة<br />إذا كانت لديك أي أسئلة إضافية عن استخدام هذا المنتج، فاسأل طبيبك أو الصيدلاني أو الممرضة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن يتسبب هذا الدواء مثل جميع الأدوية في حدوث آثار جانبية، على الرغم من عدم تعرض جميع المرضى لها.<br />توقف عن ليبانثيل 200 المسحوق واستشر الطبيب على الفور إذا لاحظت حدوث أيٍ من الآثار الجانبية الخطيرة التالية &ndash;<br />قد تحتاج إلى رعاية طبية عاجلة:</p><p>&bull; تفاعل الحساسية - قد تشمل العلامات تورم الوجه أو الشفاه أو اللسان أو الحلق مما قد يؤدي إلى صعوبة في التنفس<br />&bull; التقلص أو الألم أو اللين أو الضعف في العضلات &ndash; قد تكون هذه علامات على التهاب أو انهيار العضلات، والذي<br />يمكن أن يؤدي إلى تلف الكلى أو حتى الوفاة<br />&bull; ألم المعدة - قد يكون هذا علامة على أن البنكرياس ملتهب<br />&bull; ألم الصدر والإحساس بانقطاع النفس &ndash; قد تكون هذه علامات على وجود جلطة دموية في الرئة(الانصمام<br />الرئوي9<br />&bull; الألم أو احمرار الساقين أو تورمهما &ndash; قد تكون هذه علامات على وجود جلطة دموية في الساق (تخثر الأوردة<br />العميقة)<br />&bull; اصفرار الجلد أو بياض العينين (اليرقان) أو الزيادة في إنزيمات الكبد &ndash; قد تكون هذه علامات على وجود التهاب<br />في الكبد</p><p>توقفي عن تناول ليبانثيل 200 المسحوق واستشيري طبيبًا على الفور إذا لاحظتِ حدوث أيٍ من الآثار الجانبية بالأعلى.<br />آثار جانبية أخرى تشمل:<br />الآثار الشائعة (تؤثر في نسبة تقل عن 1:10 أشخاص)<br />&bull; الإسهال<br />&bull; ألم بالمعدة<br />&bull; ريح (غازات البطن)<br />&bull; الشعور بالإعياء (غثيان)؛</p><p>&bull; الإعياء (القيء)<br />&bull; المستويات المرتفعة من إنزيمات الكبد في الدم - يظهر في الاختبارات<br />&bull; الزيادة في الهوموسيستين (ترتبط الزيادة الكبيرة في هذا الحمض في الدم بالخطر الأكبر من الإصابة بأمراض<br />القلب التاجية والسكتة الدماغية والمرض الوعائي الطرفي على الرغم من أن الارتباط السببي لم يتأكد)</p><p>&nbsp;</p><p>الآثار غير الشائعة (تؤثر في نسبة تقل عن 1:100 أشخاص)<br />&bull; الصداع<br />&bull; الحصوات الصفراوية<br />&bull; انخفاض الرغبة الجنسية<br />&bull; الطفح الجلدي أو الحكة أو بقع حمراء على الجلد<br />&bull; ارتفاع نسبة &rsquo;الكرياتينين&lsquo; الذي يُنتج بواسطة الكلى &ndash; يظهر في الاختبارات<br />&bull; التهاب البنكرياس (التهاب في البنكرياس يؤدي إلى حدوث ألم في المعدة)<br />&bull; الانصمام الخثاري: انصمام رئوي )جلطة دموية في الرئة تسبب ألمًا في الصدر وضيقًا في التنفس(، خثار وريدي<br />عميق (جلطة دموية في الساق تسبب ألمًا أو احمرارًا أو تورمًا)<br />&bull; ألم العضلات والتهاب العضلات وتشنجات وضعف العضلات</p><p>الآثار النادرة (تؤثر في نسبة تقل عن 1:1,000 أشخاص)<br />&bull; فقدان الشعر<br />&bull; ارتفاع نسبة &rsquo;اليوريا&lsquo; الذي يُنتج بواسطة الكلى &ndash; يظهر في الاختبارات<br />&bull; زيادة حساسية بشرتك لضوء الشمس وأشعة الشمس وأرائك الاستلقاء<br />&bull; الانخفاض في نسبة الهيموجلوبين (الذي ينقل الأكسجين في الدم)وخلايا الدم البيضاء &ndash; يظهر في الاختبارات<br />&bull; التهاب الكبد، أعراض قد يكون من بينها اليرقان الخفيف (تلون الجلد وبياض العينين بلون مصفر)وألم في المعدة<br />وحكة<br />&bull; فرط التحسس (التفاعل الأرجي)</p><p>الآثار الجانبية التي لا يُعرف فرصة حدوثها</p><p>&bull; حالة شديدة من الطفح الجلدي مع احمرار وتقشر وتورم في الجلد يشبه الحروق الشديدة<br />&bull; مشاكل الرئة طويلة الأمد<br />&bull; انهيار العضلات<br />&bull; مضاعفات حصوات المثانة<br />&bull; اليرقان<br />&bull; الشعور بالدوخة (الدوار)<br />&bull; الشعور بالإرهاق (الإجهاد)</p><p>إذا شعرت بأي عدم راحة غير عادية في التنفس، فأخبر طبيبك على الفور<br />إذا أصبت بأي آثار جانبية، فأخبر بها الطبيب أو الصيدلاني أو الممرضة. يشمل هذا أي آثار جانبية غير مدرجة في هذه<br />النشرة.</p><p>الإبلاغ عن الآثار الجانبية<br />إذا أصبت بأي آثار جانبية، فأخبر بها الطبيب أو الصيدلاني أو الممرضة. يشمل هذا أي آثار جانبية محتملة غير مدرجة في<br />هذه النشرة.<br />بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات بشأن سلامة هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.<br />احتفظ بهذا الدواء في العبوة الأصلية وذلك للحماية من الرطوبة.<br />يخزن في درجة حرارة أقل من 30 درجة مئوية.<br />فترة الصلاحية: 3 سنوات<br />EXP لا تستخدم دواء ليبانثيل 200 المسحوق بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونية والشريط بعد الرمز<br />(انتهاء الصلاحية). يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.<br />لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلاني الذي تتعامل معه عن كيفية<br />التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتويات ليبانثيل 200 المسحوق<br />المادة الفعالة هي فينوفيبرات. تحتوي كل كبسولة من ليبانثيل 200 المسحوق على 200 ملليجرام )ملجم( من فينوفيبرات.<br />المكونات الأخرى هي: أحادي هيدرات اللاكتوز ، سولفات لوريل الصوديوم ونشا الذرة مضاف إليه جيلاتين مسبقًا<br />وكروسبوفيدون وستيارات المغنيسيوم.</p><p>الكبسولة مصنوعة من الجيلاتين وثاني أكسيد التيتانيوم (E171)&nbsp;وأكسيد الحديد (E172)&nbsp;وايرثروسين (E127)</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل ليبانثيل 200 المسحوق ومحتويات العبوة<br />يتوفر ليبانثيل 200 المسحوق لك في شكل كبسولات صفراء من الجيلاتين الصلب.<br />يتوفر ليبانثيل 200 المسحوق في عبوات من الأشرطة التي تحتوي على 10 أو 28 أو 30 كبسولة.<br />قد لا تتوفر جميع أحجام العبوات في الأسواق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك تصريح التسويق:<br />أبوب لابوراتوريز ليميتد،<br />أبوت هاوس، فانوال بزنس بارك،</p><p>الجهة المصنعة:<br />ريسي فارم فونتين - فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            March 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lipanthyl® 200 Micronised capsules, hard
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 200 mg fenofibrate.
Excipients with known effect: each capsule contains:
-101 mg of lactose monohydrate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orange, hard gelatin capsule.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lipanthyl 200 Micronised is indicated as an adjunct to diet and other non-pharmacological treatment (e.g.<br />exercise, weight reduction) for the following:<br />- Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.<br />- Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.<br />- Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL<br />cholesterol are not adequately controlled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dietary measures initiated before therapy should be continued. Response to therapy should be monitored by<br />determination of serum lipid values. If an adequate response has not been achieved after several months (e.g. 3<br />months), complementary or different therapeutic measures should be considered.<br />Posology:<br />Adults:<br />The recommended dose is 200 mg daily administered as one capsule of Lipanthyl 200 Micronised.<br />Special populations<br />Elderly patients (&ge; 65 years old):<br />No dose adjustment is necessary. The usual dose is recommended, except for decreased renal function with<br />estimated glomerular filtration rate &lt; 60 mL/min/1.73 (see Patients with renal impairment).<br />Patients with renal impairment:<br />Fenofibrate should not be used if severe renal impairment, defined as eGFR &lt;30 mL/min per 1.73 m2, is present. If<br />eGFR is between 30 and 59 mL/min per 1.73 m2, the dose of fenofibrate should not exceed 100 mg standard or 67<br />mg micronized once daily. If, during follow-up, the eGFR decreases persistently to &lt;30 mL/min per 1.73 m2,<br />fenofibrate should be discontinued.<br />Hepatic impairment:<br />Lipanthyl 200 Micronised is not recommended for use in patients with hepatic impairment due to the lack of data.<br />Paediatric population:<br />The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established.<br />No data are available. Therefore, the use of fenofibrate is not recommended in paediatric subjects under 18 years.</p><p>Method of administration:<br />Capsules should be swallowed whole during a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormality),
- Known gallbladder disease,
- Severe renal insufficiency (estimated glomerular filtration rate < 30 mL/min/1.73 m2),
- Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia,
- Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen,
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Secondary causes of hyperlipidemia:<br />Secondary causes of hyperlipidemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic<br />syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism, should be adequately<br />treated before fenofibrate therapy is considered. Secondary cause of hypercholesterolemia related to<br />pharmacological treatment can be seen with diuretics, &beta;-blocking agents, estrogens, progestogens, combined oral<br />contraceptives, immunosuppressive agents and protease inhibitors. In these cases it should be ascertained whether<br />the hyperlipidaemia is of primary or secondary nature (possible elevation of lipid values caused by these therapeutic<br />agents).<br />Liver function:<br />As with other lipid lowering agents, increases have been reported in transaminase levels in some patients. In the<br />majority of cases these elevations were transient, minor and asymptomatic. It is recommended that transaminase<br />levels are monitored every 3 months during the first 12 months of treatment and thereafter periodically. Attention<br />should be paid to patients who develop increase in transaminase levels and therapy should be discontinued if AST<br />(SGOT) and ALT (SGPT) levels increase to more than 3 times the upper limit of the normal range. When symptoms<br />indicative of hepatitis occur (e.g. jaundice, pruritus), and diagnosis is confirmed by laboratory testing, fenofibrate<br />therapy should be discontinued.<br />Pancreas:<br />Pancreatitis has been reported in patients taking fenofibrate (see sections 4.3 and 4.8). This occurrence may<br />represent a failure of efficacy in patients with severe hypertriglyceridaemia, a direct drug effect, or a secondary<br />phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.</p><p>Muscle:<br />Muscle toxicity, including rare cases of rhabdomyolysis, with or without renal failure has been reported with<br />administration of fibrates and other lipid-lowering agents. The incidence of this disorder increases in cases of<br />hypoalbuminaemia and previous renal insufficiency. Patients with pre-disposing factors for myopathy and/or<br />rhabdomyolysis, including age above 70 years, personal or familial history of hereditary muscular disorders, renal<br />impairment, hypothyroidism and high alcohol intake, may be at an increased risk of developing rhabdomyolysis. For<br />these patients, the putative benefits and risks of fenofibrate therapy should be carefully weighed up.<br />Muscle toxicity should be suspected in patients presenting diffuse myalgia, myositis, muscular cramps and weakness<br />and/or marked increases in CPK (levels exceeding 5 times the normal range). In such cases treatment with<br />fenofibrate should be stopped.<br />The risk of muscle toxicity may be increased if the drug is administered with another fibrate or an HMG-CoA<br />reductase inhibitor, especially in cases of pre-existing muscular disease. Consequently, the co-prescription of<br />fenofibrate with a HMG-CoA reductase inhibitor or another fibrate should be reserved to patients with severe<br />combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and a close monitoring<br />of potential muscle toxicity.</p><p>Renal function:<br />Lipanthyl 200 Micronised is contraindicated in severe renal impairment (see section 4.3).<br />Lipanthyl 200 Micronised should be used with caution in patients with mild to moderate renal insufficiency. Dose<br />should be adjusted in patients whose estimated glomerular filtration rate is 30 to 59 mL/min/1.73 m2 (see section<br />4.2).<br />Reversible elevations in serum creatinine have been reported in patients receiving fenofibrate monotherapy or coadministered<br />with statins. Elevations in serum creatinine were generally stable over time with no evidence for<br />continued increases in serum creatinine with long term therapy and tended to return to baseline following<br />discontinuation of treatment.<br />During clinical trials, 10% of patients had a creatinine increase from baseline greater than 30 &mu;mol/L with coadministered<br />fenofibrate and simvastatin versus 4.4% with statin monotherapy. 0.3% of patients receiving coadministration<br />had clinically relevant increases in creatinine to values &gt; 200 &mu;mol/L.<br />Treatment should be interrupted when creatinine level is 50% above the upper limit of normal. It is recommended that<br />creatinine is measured during the first 3 months after initiation of treatment and periodically thereafter.<br />Excipients:<br />As this medicinal product contains Lactose, patients with rare hereditary problems of galactose intolerance, the Lapp<br />lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral Anti-coagulants<br />Fenofibrate enhances oral anti-coagulant effect and may increase risk of bleeding. In patients receiving oral anticoagulant<br />therapy, the dose of anti-coagulant should be reduced by about one-third at the commencement of<br />treatment and then gradually adjusted if necessary according to INR (International Normalised Ratio) monitoring.<br />Cyclosporin<br />Some severe cases of reversible renal function impairment have been reported during concomitant administration of<br />fenofibrate and cyclosporin. The renal function of these patients must therefore be closely monitored and the<br />treatment with fenofibrate stopped in the case of severe alteration of laboratory parameters.<br />HMG-CoA reductase inhibitors or Other Fibrates<br />The risk of serious muscle toxicity is increased if a fibrate is used concomitantly with HMG-CoA reductase inhibitors or<br />other fibrates. Such combination therapy should be used with caution and patients monitored closely for signs of<br />muscle toxicity (see section 4.4.).<br />There is currently no evidence to suggest that fenofibrate affects the pharmacokinetics of simvastatin.<br />Glitazones<br />Some cases of reversible paradoxical reduction of HDL-cholesterol have been reported during concomitant<br />administration of fenofibrate and glitazones. Therefore it is recommended to monitor HDL-cholesterol if one of these<br />components is added to the other and stopping of either therapy if HDL-cholesterol is too low.</p><p>Cytochrome P450 enzymes<br />In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of<br />cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19<br />and CYP2A6, and mild-to-moderate of CYP2C9 at therapeutic concentrations.<br />Patients co-administered fenofibrate and CYP2C19, CYP2A6, and especially CYP2C9 metabolised drugs with a<br />narrow therapeutic index should be carefully monitored and, if necessary, dose adjustment of these drugs is<br />recommended.<br />Other<br />In common with other fibrates, fenofibrate induces microsomal mixed-function oxidases involved in fatty acid<br />metabolism in rodents and may interact with drugs metabolised by these enzymes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: There are no adequate data from the use of fenofibrate in pregnant women. Animal studies have not<br />demonstrated any teratogenic effects. Embryotoxic effects have been shown at doses in the range of maternal toxicity<br />(see section 5.3). The potential risk for humans is unknown.<br />Therefore, Lipanthyl 200 Micronised should only be used during pregnancy after a careful benefit/risk assessment.</p><p>Lactation: It is unknown whether fenofibrate and/or its metabolites are excreted in human milk. A risk to the suckling<br />child cannot be excluded. Therefore fenofibrate should not be used during breast-feeding.<br />Fertility: Reversible effects on fertility have been observed in animals (see section 5.3). There are no clinical data on<br />fertility from the use of Lipanthyl 200 Micronised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lipanthyl 200 Micronised has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported ADRs during Lipanthyl therapy are digestive, gastric or intestinal disorders.<br />The following undesirable effects have been observed during placebo-controlled clinical trials (n=2344) with the below<br />indicated frequencies:</p><table border="1" cellspacing="1" cellpadding="1" style="width:1289px"><tbody><tr><td style="width:184px">MedDRA system<br />organ class</td><td style="width:298px">Common<br />&ge;1/100, &lt;1/10</td><td style="width:291px">Uncommon<br />&ge;1/1,000, &lt;1/100</td><td style="width:295px">Rare&nbsp;&ge;1/10,000, &lt;1/1,000</td><td style="width:219px">Very rare&nbsp;&lt;1/10,000<br />incl. isolated<br />reports</td></tr><tr><td style="width:184px">Blood and lymphatic<br />system disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">&nbsp;</td><td style="width:295px">Haemoglobin<br />decreased<br />White blood cell count<br />decreased</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Immune system<br />disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">&nbsp;</td><td style="width:295px">Hypersensitivity</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Nervous system<br />disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">Headache</td><td style="width:295px">&nbsp;</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Vascular disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">Thromboembolism<br />(pulmonary embolism,<br />deep vein thrombosis)*</td><td style="width:295px">&nbsp;</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Gastrointestinal<br />disorders</td><td style="width:298px">Gastrointestinal signs&nbsp;and symptoms<br />(abdominal pain,<br />nausea, vomiting,<br />diarrhoea, flatulence)</td><td style="width:291px">Pancreatitis*</td><td style="width:295px">&nbsp;</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Hepatobiliary disorders</td><td style="width:298px">Transaminases<br />increased (see section<br />4.4)</td><td style="width:291px">Cholelithiasis (see section 4.4)</td><td style="width:295px">Hepatitis</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Skin and subcutaneous<br />tissue disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">Cutaneous hypersensitivity&nbsp;(e.g. Rashes, pruritus,&nbsp;urticaria)</td><td style="width:295px"><p>Alopecia&nbsp;</p><p>Photosensitivity&nbsp;reactions</p></td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Musculoskeletal,<br />connective tissue and<br />bone disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">Muscle disorder (e.g.<br />myalgia, myositis,<br />muscular spasms and<br />weakness)</td><td style="width:295px">&nbsp;</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Reproductive system<br />and breast disorders</td><td style="width:298px">&nbsp;</td><td style="width:291px">Sexual dysfunction</td><td style="width:295px">&nbsp;</td><td style="width:219px">&nbsp;</td></tr><tr><td style="width:184px">Investigations</td><td style="width:298px">Blood homocysteine<br />level increased**</td><td style="width:291px">Blood creatinine increased</td><td style="width:295px">Blood urea increased</td><td style="width:219px">&nbsp;</td></tr></tbody></table><p>* In the FIELD-study, a randomized placebo-controlled trial performed in 9795 patients with type 2 diabetes mellitus, a<br />statistically significant increase in pancreatitis cases was observed in patients receiving fenofibrate versus patients<br />receiving placebo (0.8% versus 0.5%; p = 0.031). In the same study, a statistically significant increase was reported in<br />the incidence of pulmonary embolism (0.7% in the placebo group versus 1.1% in the fenofibrate group; p = 0.022) and<br />a statistically non-significant increase in deep vein thromboses (placebo: 1.0 % [48/4900 patients] versus fenofibrate<br />1.4% [67/4895 patients]; p = 0.074).<br />** In the FIELD study the average increase in blood homocysteine level in patients treated with fenofibrate was 6.5<br />&mu;mol/L, and was reversible on discontinuation of fenofibrate treatment. The increased risk of venous thrombotic<br />events may be related to the increased homocysteine level. The clinical significance of this is not clear.<br />In addition to those events reported during clinical trials, the following side effects have been reported spontaneously</p><p>&nbsp;</p><p>during postmarketing use of Lipanthyl. A precise frequency cannot be estimated from the available data and is<br />therefore classified as &ldquo;not known&rdquo;.<br />- Respiratory, thoracic and mediastinal disorders: Interstitial lung disease.<br />- Musculoskeletal, connective tissue and bone disorders: Rhabdomyolysis.<br />- Hepatobiliary disorders: jaundice, complications of cholelithiasis (e.g. cholecystitis, cholangitis, biliary colic)<br />- Skin and Subcutaneous Tissue Disorders: severe cutaneous reactions (e.g erythema multiforme, Stevens-Johnson<br />syndrome, toxic epidermal necrolysis)<br />- General disorders and administration site conditions: Fatigue<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued<br />monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any<br />suspected adverse reactions directly.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only anecdotal cases of fenofibrate overdosage have been received. In the majority of cases no overdose symptoms<br />were reported.<br />No specific antidote is known. If overdose is suspected, treat symptomatically and institute appropriate supportive<br />measures as required. Fenofibrate cannot be eliminated by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Serum Lipid Reducing Agents/Cholesterol and Triglyceride Reducers/Fibrates. ATC code:C10 AB 05.<br />Lipanthyl 200 Micronised is a formulation containing 200mg of micronised fenofibrate.<br />Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of<br />Peroxisome Proliferator Activated Receptor type &alpha; (PPAR&alpha;). Through activation of PPAR&alpha;, fenofibrate increases<br />lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and<br />reducing production of Apoprotein C-III. Activation of PPAR&alpha; also induces an increase in the synthesis of Apoproteins<br />A-I, and A-II.<br />There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been<br />shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease.<br />The Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial was a randomized placebo-controlled<br />study of 5518 patients with type 2 diabetes mellitus treated with fenofibrate in addition to simvastatin. Fenofibrate plus<br />simvastatin therapy did not show any significant differences compared to simvastatin monotherapy in the composite<br />primary outcome of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death (hazard ratio [HR] 0.92,<br />95% CI 0.79-1.08, p = 0.32 ; absolute risk reduction: 0.74%). In the pre-specified subgroup of dyslipidaemic patients,<br />defined as those in the lowest tertile of HDL-C (&le;34 mg/dl or 0.88 mmol/L) and highest tertile of TG (&ge;204 mg/dl or 2.3<br />mmol/L) at baseline, fenofibrate plus simvastatin therapy demonstrated a 31% relative reduction compared to<br />simvastatin monotherapy for the composite primary outcome (hazard ratio [HR] 0.69, 95% CI 0.49-0.97, p = 0.03;<br />absolute risk reduction: 4.95%). Another prespecified subgroup analysis identified a statistically significant treatment-</p><p>by-gender interaction (p = 0.01) indicating a possible treatment benefit of combination therapy in men (p=0.037) but a<br />potentially higher risk for the primary outcome in women treated with combination therapy compared to simvastatin</p><p>monotherapy (p=0.069). This was not observed in the aforementioned subgroup of patients with dyslipidaemia but<br />there was also no clear evidence of benefit in dyslipidaemic women treated with fenofibrate plus simvastatin, and a<br />possible harmful effect in this subgroup could not be excluded.<br />Studies with fenofibrate on lipoprotein fractions show decreases in levels of LDL and VLDL cholesterol. HDL<br />cholesterol levels are frequently increased. LDL and VLDL triglycerides are reduced. The overall effect is a decrease<br />in the ratio of low and very low density lipoproteins to high density lipoproteins, which epidemiological studies have<br />correlated with a decrease in atherogenic risk. Apolipoprotein-A and apolipoprotein-B levels are altered in parallel with<br />HDL and LDL and VLDL levels respectively.<br />Extravascular deposits of cholesterol (tendinous and tuberous xanthoma) may be markedly reduced or even entirely<br />eliminated during fenofibrate therapy.<br />Plasma uric acid levels are increased in approximately 20% of hyperlipidaemic patients, particularly in those with type<br />IV disease.<br />Patients with raised levels of fibrinogen treated with fenofibrate have shown significant reductions in this parameter,<br />as have those with raised levels of Lp(a). Other inflammatory markers such as C Reactive Protein are reduced with<br />fenofibrate treatment.<br />The uricosuric effect of fenofibrate leading to reduction in uric acid levels of approximately 25% should be of<br />additional benefit in those dyslipidaemic patients with hyperuricaemia.<br />Fenofibrate has been shown to possess an anti-aggregatory effect on platelets in animals and in a clinical study,<br />which showed a reduction in platelet aggregation induced by ADP, arachidonic acid and epinephrine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />Maximum plasma concentrations (Cmax) occur within 4 to 5 hours after oral administration. Plasma concentrations<br />are stable during continuous treatment in any given individual.<br />The absorption of fenofibrate is increased when administered with food.<br />Distribution:<br />Fenofibric acid is strongly bound to plasma albumin (more than 99%).<br />Metabolism and excretion:<br />After oral administration, fenofibrate is rapidly hydrolised by esterases to the active metabolite fenofibric acid.<br />No unchanged fenofibrate can be detected in the plasma. Fenofibrate is not a substrate for CYP 3A4. No hepatic<br />microsomal metabolism is involved.<br />The drug is excreted mainly in the urine. Practically all the drug is eliminated within 6 days. Fenofibrate is mainly<br />excreted in the form of fenofibric acid and its glucuronoconjugate.<br />In elderly patients, the fenofibric acid apparent total plasma clearance is not modified.<br />Kinetic studies following the administration of a single dose and continuous treatment have demonstrated that the<br />drug does not accumulate.<br />Fenofibric acid is not eliminated during haemodialysis.<br />The plasma elimination half-life of fenofibric acid is approximately 20 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a three-month oral nonclinical study in the rat species with fenofibric acid, the active metabolite of fenofibrate,<br />toxicity for the skeletal muscles (particularly those rich in type I -slow oxidative- myofibres) and cardiac degeneration,</p><p>anaemia and decreased body weight were seen. No skeletal toxicity was noted at doses up to 30 mg/kg<br />(approximately 17-time the exposure at the human maximum recommended dose (MRHD). No signs of<br />cardiomyotoxicity were noted at an exposure about 3 times the exposure at MRHD. Reversible ulcers and erosions in<br />the gastro-intestinal tract occurred in dogs treated for 3 months. No gastro-intestinal lesions were noted in that study<br />at an exposure approximately 5 times the exposure at the MRHD.<br />Studies on the mutagenicity of fenofibrate have been negative.<br />In rats and mice, liver tumours have been found at high dosages which are attributable to peroxisome proliferation.<br />These changes are specific to small rodents and have not been observed in other animal species. This is of no<br />relevance to therapeutic use in man. Studies in mice, rats and rabbits did not reveal any teratogenic effect.<br />Embryotoxic effects were observed at doses in the range of maternal toxicity. Prolongation of the gestation period and<br />difficulties during delivery were observed at high doses.<br />Reversible hypospermia and testicular vacuolation and immaturity of the ovaries were observed in a repeat-dose<br />toxicity study with fenofibric acid in young dogs. However no effects on fertility were detected in non-clinical<br />reproductive toxicity studies conducted with fenofibrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients: lactose monohydrate, pregelatinised starch, sodium laurilsulfate, crospovidone and magnesium stearate.<br />Composition of the capsule shell: gelatin, titanium dioxide (E171), red iron oxide (E172) and yellow iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effect noted to date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep in dry place. Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack of 10, 28, 30 capsules in blisters (PVC/Aluminium).<br />*Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories Ltd.
Abbott House, Vanwall Business park
Vanwall Road, Maidenhead Berkshire
SL6 4XE, UK
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mar 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>